Smaller HDL particles are associated with absence of obstructive coronary artery disease in stable angina pectoris patients by Zeljković, Aleksandra et al.
Short Report
Smaller HDL particles are associated with absence
of obstructive coronary artery disease in stable angina
pectoris patients
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Abstract
Background: A research on novel cardiovascular risk factors is mainly focused on patients with clinically verified
coronary artery disease (CAD), while less is known about their presence in symptomatic patients, but without angio-
graphically proven occlusion of coronary arteries. The aim of this study was to compare plasma low-density lipoprotein
(LDL) and high-density lipoprotein (HDL) size and subclasses in stable angina patients with and without significant
obstructive CAD.
Methods: LDL and HDL subclasses were analysed in 100 stable angina patients with 550% of obstruction and 40
patients with less than 50% of luminal narrowing, as assessed by coronary angiography.
Results: Patients with <50% of obstruction had reduced mean HDL size and higher proportion of small HDL particles
(P< 0.05). HDL size and proportion of small HDL particles were significant and independent predictors of obstructive
CAD (P< 0.05, respectively).
Conclusions: Stable angina patients with <50% of coronary obstruction have more favourable HDL subclasses distri-
bution than patients with significant coronary stenosis.
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Introduction
Majority of studies on novel cardiovascular risk factors
have been focused on patients with clinically signiﬁcant
coronary artery disease (CAD). Less is known about
the presence and interrelationship of risk factors in
symptomatic patients, but without angiographic evi-
dences of signiﬁcant coronary occlusion.1 Screening
for the presence of small, dense low-density lipoprotein
(LDL) and high-density lipoprotein (HDL) particles
and identiﬁcation of factors which aﬀect their excessive
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production could have beneﬁcial eﬀects on reducing the
risk for future cardiovascular events.2 Yet, clinical sig-
niﬁcance of LDL and HDL particles heterogeneity in
patients with stable angina, but without coronary
occlusion remains to be established.
The aim of this study was to compare plasma LDL
and HDL size and subclasses in stable angina patients
with and without angiographically veriﬁed coronary
obstruction. In addition, we sought to examine whether
potential diﬀerences in lipoprotein subclasses distribu-
tions could be related to the progression of the disease.
Patients and methods
This study included 140 patients with stable angina pec-
toris referred for elective coronary angiography at the
Institute of Cardiovascular Diseases, Clinical Centre of
Serbia in Belgrade. Stable angina was deﬁned by its
clinical presentation of chest pain or discomfort that
typically occurs with activity or emotional stress and
relieves by organic nitrates administration or rest.
Exclusion criteria were acute myocardial infarction
within three months prior to analyses, presence of infec-
tion, diabetes, renal and hepatic disorders, or use of
lipid-lowering drugs. Two experienced cardiologists,
unaware of patients’ clinical history and biochemical
results visually reviewed all angiographic images to
assess the extent of CAD. Signiﬁcant lesions with
550% of luminal narrowing were found in 100
patients, while rest of 40 patients had less of 50% of
obstruction. Informed consent was obtained from each
participant. The study was executed according to the
Helsinki Declaration and approved by the institutional
review committee (Reference No. 2251/1).
Plasma LDL and HDL subclasses proﬁles were
assessed using a method of polyacrylamide gradient
gel electrophoresis.3 Estimated diameter of the major
peak in the LDL and HDL regions of densitometric
scan was referred to as LDL and HDL particle size
and relative content of each subclass was estimated by
determining the areas under the peaks. The inter-assay
coeﬃcients of variations (CV) for LDL and HDL sizes
were 1.8–2.2% and the method was highly correlated
with the original procedure (Y-intercept: 1.14 0.76,
slope: 0.96 0.03, r2¼ 0.992).3 Apolipoprotein E
(apoE) phenotyping was performed by isoelectric focus-
ing of delipidated serum followed by immunobloting.
Visceral adiposity index (VAI) was calculated as previ-
ously proposed.4 Concentrations of other analysed par-
ameters were assayed by routine laboratory methods.
Continuous variables are presented as mean and
standard deviations and analysed by the Student’s t
test; or as median and interquartile range and analysed
by the Mann–Whitney U test. Categorical variables are
presented as relative frequencies and compared by the
Chi-square test. Univariate and multivariate logistic
regression analysis were used to examine the associ-
ations of HDL size and relative proportion of small
HDL particles with obstructive CAD. Diﬀerences
with P< 0.05 were considered to be statistically
signiﬁcant.
Results
Clinical and laboratory characteristics of patients are
summarized in Table 1. The two examined groups were
uniform by age, body mass index (BMI), waist circum-
ference, VAI and prevalence of hypertension (HTA).
Serum total cholesterol (TC) and LDL-cholesterol
(LDL-C) were higher and HDL-cholesterol (HDL-C)
was lower in group with 550% of coronary obstruc-
tion. Triglycerides (TG), LDL size, proportion of small,
dense LDL particles and distribution of apoE alleles
did not diﬀer between the groups. However, patients
with <50% of obstruction had smaller mean HDL
size, as well as higher proportion of small particles in
total HDL distribution.
Further analysis was focused on patients with HDL
size 48.8 nm (16 patients with <50% and 23 patients
with 550% of coronary obstruction). Even though
both newly formed groups were homogenous by age,
gender, BMI and waist circumference (data not
shown), patients with 550% of coronary occlusion
had greater VAI [5.27 (3.40–9.65) vs. 4.17 (2.15–6.09);
P< 0.05] and TG [2.60 (1.94–3.12) vs. 1.86 (1.34–2.50)
mmol/L; P< 0.05], while lower HDL-C [0.72 0.16 vs.
0.87 0.22mmol/L; P< 0.05] and apoA-I [1.3 0.2 vs.
1.5 0.2 g/L; P< 0.01] levels. In occlusive CAD group,
distribution of LDL subclasses was shifted in favour of
small, dense particles (425.5 nm), due to the reduction
in relative proportion of LDL I [38.2 14.6 vs.
50.8 11.0%; P< 0.01] and increase of LDL IV
[25.9 11.3 vs. 17.1 8.1%; P< 0.01] subclasses.
Finally, in order to estimate independent association
of small HDL particles to the risk for development of
occlusive CAD, we performed logistic regression ana-
lysis (Table 2). Increased HDL size and decreased pro-
portion of small HDL particles were signiﬁcantly
associated with occlusive CAD. After we performed
adjustment for all other analysed variables, both HDL
size and proportion of small HDL particles remained
signiﬁcant determinants of obstructive disease.
Discussion
In the present study we have demonstrated that stable
angina patients without angiographically documented
coronary occlusion have diﬀerent HDL particles distri-
bution than the patients with signiﬁcant luminal
narrowing.
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Table 1. Clinical and laboratory characteristics of study participants according to the results of coronary angiography.
Coronary obstruction,
<50% (n¼ 40)
Coronary obstruction,
550% (n¼ 100) P
Age, years 53.5 11.0 56.4 8.3 0.083
Gender, male % 50.0 71.0 <0.05
BMI, kg/m2 29.3 4.7 27.7 3.3 0.080
Waist circumference, cm 98.2 12.7 97.9 11.7 0.907
VAI* 3.63 (2.02–6.78) 4.11 (3.08–5.60) 0.250
HTA, %y 92.5 85.0 0.232
TC, mmol/L 4.95 1.10 5.50 1.03 <0.01
TG, mmol/L* 1.88 (1.33–2.80) 2.11 (1.61–2.69) 0.296
LDL-C, mmol/L 3.33 1.04 3.76 0.96 <0.05
HDL-C, mmol/L 0.87 0.22 0.79 0.19 <0.05
ApoA-I, g/L 1.4 0.3 1.4 0.3 0.124
ApoB, g/L 1.3 0.3 1.4 0.3 <0.01
hsCRP, mg/L* 2.5 (1.6–7.3) 3.6 (2.2–10.8) 0.113
Fibrinogen, g/L 5.4 1.5 5.8 1.7 0.226
Uric acid, mmol/L 314 93 376 91 <0.001
LDL size, nm 25.8 1.8 25.8 1.4 0.999
Small, dense LDL (425.5 nm), % 45.0 18.2 45.6 17.3 0.856
HDL size, nm 9.3 1.1 9.8 1.2 <0.05
Small HDL particles (48.8 nm), % 40.1 24.7 30.5 22.7 <0.05
Apo E allele "2, % 6.3 3.0 0.449
Apo E allele "3, % 78.7 81.5
Apo E allele "4, % 15.0 15.5
Continuous variables are presented as mean standard deviation and compared by the Student’s t test, whereas categorical variables
are presented as relative frequencies and compared by the Chi-square test.
*Values are presented as median (interquartile range) and compared by the Mann–Whitney U test.
yHypertension (HTA) was defined by a systolic blood pressure5130mm Hg, diastolic blood pressure585mm Hg or the use of any
antihypertensive medication.
Table 2. Logistic regression analysis for associations of HDL size and relative proportion of small HDL particles with obstructive
CAD.
HDL size, nm Small HDL particles, %
OR (95% CI) P OR (95% CI) P
Univariate analysis 1.46 (1.04–2.06) <0.05 0.98 (0.97–0.99) <0.05
Adjusted for
Age, gender, smoking, BMI, VAI 1.61 (1.08–2.39) <0.05 0.97 (0.95–0.99) <0.01
HDL-C and apoA-I 1.50 (1.05–2.15) <0.05 0.98 (0.97–0.99) <0.05
TC, TG, LDL-C and apoB 1.58 (1.09–2.30) <0.05 0.98 (0.96–0.99) <0.01
Presence of "2 allele 1.48 (1.04–2.10) <0.05 0.98 (0.97–0.99) <0.05
Presence of "4 allele 1.46 (1.04–2.06) <0.05 0.98 (0.97–0.99) <0.05
Fibrinogen, hsCRP and uric acid 1.45 (1.01–2.03) <0.05 0.98 (0.96–0.99) <0.05
All previous confounders 2.05 (1.12–3.73) <0.05 0.96 (0.94–0.99) <0.01
HDL size and percentage of small HDL particles were entered as continuous variables. Confounding variables were entered as continuous, except for:
gender (0, female; 1, male), smoking status (0, nonsmokers; 1, smokers) and presence of "2 and "4 alleles (0, absent; 1, present).
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Alber et al.1 reported that HDL-C was independ-
ently associated with prevalence and severity of CAD.
It is now appreciated that plasma HDL-C level cannot
reﬂect HDL particles diversity or capture their func-
tional variations.5 Accordingly, it has been postulated
that small HDLs generally have stronger cardioprotec-
tive properties than their larger counterparts.5 Our ﬁnd-
ings of higher HDL-C, reduced HDL size and increased
prevalence of small HDL particles in the group with
<50% of coronary obstruction (Table 1) are in agree-
ment with this explanation. However, it has been
noticed that small HDL particles can be highly vulner-
able to possible detrimental eﬀects of dyslipidemia,
enhanced oxidative stress and inﬂammation, which
could decrease their anti-atherogenic capacity.5 In the
current study, smaller HDL size was accompanied with
signiﬁcantly higher TG and VAI in patients with sig-
niﬁcant stenosis. Therefore, we could speculate that
prominent hypertriglyceridemia and possible insulin
resistance in this category of patients could compromise
HDL’s atheroprotective function. Such particles are
likely to have diminished ability to prevent lipid accu-
mulation and formation of plaque,5 which could be
partly reﬂected as enhanced proportion of small,
dense LDL particles in these patients. Indeed, smaller
HDL size and a preponderance of small particles were
associated with reduced risk for severe luminal narrow-
ing and consequently, obstructive CAD development
(Table 2). Observed independent associations suggest
the existence of intrinsic mechanisms through which
HDL particles per se contribute to preservation of
normal arterial lumen, regardless of other cardiovascu-
lar risk factors.
Relatively small sample size might restrict a reliabil-
ity of our conclusions. Also, we could not explore a
causal relationship between HDL particles distribution
and progression of luminal stenosis in later life. Future
prospective studies are needed to evaluate presented
observations.
In conclusion, our results demonstrated diﬀerences
in HDL subclasses distribution in stable angina patients
with and without angiographically veriﬁed obstructive
CAD, with a shift towards smaller particles in the
non-obstructive group. Our results indicate that the
observed diﬀerence might be accounted for reduced
risk of CAD progression towards obstructive disease.
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